Table 1. Demographic and clinical characteristics of the subjects enrolled in the study.
| HIV-uninfected | HIV-infected | |||||
|---|---|---|---|---|---|---|
| TB | LTBI | HIV-TB | HIV-LTBI | Total | p value | |
| N (%) | 13 (26.5) | 9 (18.4) | 12 (24.5) | 15 (30.6) | 49 (100) | |
| Median Age (IQR) | 30.0 (25.0–46.0) | 48.0 (34.5–60.0) | 40.0 (30.3–44.0) | 38.0 (35.0–40.0) | 38.0 (30.5–44.5) | 0.3a |
| Female gender (%) | 1 (7.7) | 1 (11.1) | 0 | 3 (20.0) | 5 (10.2) | 0.4b |
| Origin (%) | 0.001b | |||||
| Italy | 2 (15.4) | 6 (66.7) | 3 (25.0) | 1 (6.7) | 12 (24.5) | |
| Eastern Europe | 9 (69.2) | 1 (11.1) | 5 (41.6) | 3 (20.0) | 18 (36.7) | |
| Asia | 1 (7.7) | - | - | - | 1 (2.0) | |
| Africa | 1 (7.7) | 2 (22.2) | 2 (16.7) | 2 (13.3) | 7 (14.3) | |
| South America | - | - | 2 (16.7) | 9 (60.0) | 11 (22.5) | |
| BCG status (%) | 0.008b | |||||
| Vaccinated | 11 (84.6) | 3 (33.3) | 9 (75.0) | 14 (93.3) | 37 (75.5) | |
| Unvaccinated | 2 (15.4) | 6 (66.7) | 3 (25.0) | 1 (6.7) | 12 (24.5) | |
| QFT-IT (%) | 0.24b | |||||
| Positive | 11 (84.6) | 9 (100) | 10 (83.4) | 15 (100) | 45 (91.8) | |
| Negative | 2 (15.4) | - | 2 (16.7) | - | 4 (8.2) | |
| CD4+ T-cell/mm3
# Median (IQR) |
- | - | 128.5 (41.0–266.5) |
666 (341.0–1075.0) |
329 (110.0–767.0) |
0.0001c |
| CD8+ T-cell/mm3
# Median (IQR) |
- | - | 532.5 (153.3–815.0) |
1053 (884.0–1352.0) |
877 (481.0–1287.0) |
0.0001c |
| HIV-RNA (cp/μl) # Median (IQR) |
- | - | 60542.0 (7451.8–610654.3) |
6878.0 (1427.5–24809.0) |
16689.0 (1884–150192.0) |
0.035c |
HIV: human immunodeficiency virus; LTBI: latent tuberculosis infection; TB: active tuberculosis; IQR: interquartile range; BCG: Bacillus Calmette et Guérin; QFT-IT: QuantiFERON-TB Gold (QFT®) in tube;
#: only available for HIV-infected patients.
a Kruskal-Wallis test.
b Chi-square test.
c Mann-Whitney.